News
Blue Arbor Technologies Secures $10.5 Million to Revolutionize Prosthetic Control
FundingOctober 31, 2026, 3:32 pm
Michigan-based Blue Arbor Technologies has closed a $10.5 million Series A funding round. This significant investment, led by global leader Ottobock, propels the company’s RESTORE Neuromuscular Interface System. The RESTORE platform seeks to redefine prosthetic control for individuals with limb loss. Funds will accelerate feasibility studies, secure crucial FDA approvals, and advance development of a fully implantable interface. Blue Arbor’s innovation promises unprecedented dexterity and intuitive control, building on successful human trials and critical FDA Breakthrough Device Designation. This funding marks a pivotal step in closing the gap between current prosthetic capabilities and future potential.
Michigan-based Blue Arbor Technologies has made a major leap forward. The company announced the close of a $10.5 million Series A funding round. This capital infusion will accelerate development of its groundbreaking RESTORE Neuromuscular Interface System. The system promises a new era of prosthetic control for individuals with limb loss. Ottobock, a global leader in prosthetics and bionics, led the funding round. This strategic partnership underscores the potential impact of Blue Arbor’s technology. The investment signifies confidence in the RESTORE system’s ability to transform lives.
The RESTORE Neuromuscular Interface System is Blue Arbor’s flagship innovation. It targets a fundamental challenge: connecting a patient’s nervous system directly to a robotic prosthetic. Current prosthetic systems often lack intuitive, precise control. RESTORE aims to bridge this gap. The technology enables independent and simultaneous control of fingers, wrist, and elbow. This translates to vastly improved dexterity, speed, and reliability. For users, it means a more natural and functional interaction with their advanced prosthetic devices. The system is designed for people seeking greater functionality from their artificial limbs.
Blue Arbor is developing two versions of the RESTORE platform. The external sensing unit represents the initial phase. It is currently undergoing feasibility studies. This unit allows for non-invasive testing and validation of the core technology. The long-term vision includes a fully implantable internal sensing unit. This next-generation interface will integrate seamlessly into the same RESTORE platform. It offers the promise of maximum comfort, discretion, and connectivity for users. Both versions share the goal of creating a direct, intuitive link between mind and machine.
The $10.5 million Series A funding will fuel critical development pathways. A primary objective is completing feasibility studies for the external sensing unit. These studies are essential for gathering performance data and refining the technology. The company will also pursue an FDA Investigational Device Exemption (IDE). An IDE is crucial for initiating U.S. clinical studies for the external sensing unit. These trials will validate the system's safety and effectiveness in a broader patient population. Concurrently, Blue Arbor will begin developing the fully implantable internal sensing unit. This dual-track approach ensures both immediate progress and long-term innovation.
Blue Arbor Technologies has already achieved significant milestones. The company has completed two human implantations of its technology. A successful second-in-human procedure recently occurred at the Medical University of Vienna. These initial procedures provide vital real-world data and validation. The RESTORE system has also garnered recognition from leading research institutions. It was selected for a University of Michigan clinical study. This study, backed by an NIH UG3 grant, will compare surface electrodes with implanted electrodes for prosthetic control. Such independent validation reinforces the system's scientific merit.
Regulatory bodies have also acknowledged the RESTORE system's potential. The platform received FDA Breakthrough Device Designation. This designation is reserved for technologies that offer more effective treatment or diagnosis of life-threatening or irreversibly debilitating conditions. It streamlines the regulatory review process. Furthermore, Blue Arbor has been accepted into the FDA’s Total Product Life Cycle Advisory Program Pilot. This program provides early interaction with FDA experts. Both recognitions highlight the agency’s belief in RESTORE’s transformative capacity. They signal a path toward expedited patient access.
The investment from Ottobock represents more than just capital. Ottobock is a global leader in prosthetics, neuro-orthotics, and wearable human bionics. Its involvement provides strategic partnership and deep industry expertise. Ottobock’s vast distribution network and market presence offer Blue Arbor unparalleled opportunities. This collaboration can accelerate the translation of pioneering research into scalable solutions. It positions Blue Arbor to deliver meaningful value to millions worldwide living with limb loss. The partnership creates a powerful alliance between cutting-edge innovation and established market leadership.
Blue Arbor Technologies is based in Grass Lake, Michigan. The company's mission is clear. It aims to create a direct, intuitive connection between a patient’s peripheral nervous system and a robotic prosthetic limb. This connection is the key to unlocking superior control and functionality. For individuals who have lost limbs, this technology promises a return to more natural movement. It offers increased independence and an improved quality of life. The RESTORE system represents a significant step towards fulfilling this promise.
This funding round marks a pivotal moment for Blue Arbor and the field of prosthetic control. It fuels the development of a technology poised to redefine human-machine interaction. The company is committed to closing the gap between current prosthetic technology and the needs of patients. With successful human implantations, critical FDA designations, and strong strategic backing, Blue Arbor Technologies is well-positioned. It stands ready to deliver the next generation of intuitive and precise prosthetic control systems. The future of bionic limbs looks more connected, more intuitive, and more hopeful.
Michigan-based Blue Arbor Technologies has made a major leap forward. The company announced the close of a $10.5 million Series A funding round. This capital infusion will accelerate development of its groundbreaking RESTORE Neuromuscular Interface System. The system promises a new era of prosthetic control for individuals with limb loss. Ottobock, a global leader in prosthetics and bionics, led the funding round. This strategic partnership underscores the potential impact of Blue Arbor’s technology. The investment signifies confidence in the RESTORE system’s ability to transform lives.
The RESTORE Neuromuscular Interface System is Blue Arbor’s flagship innovation. It targets a fundamental challenge: connecting a patient’s nervous system directly to a robotic prosthetic. Current prosthetic systems often lack intuitive, precise control. RESTORE aims to bridge this gap. The technology enables independent and simultaneous control of fingers, wrist, and elbow. This translates to vastly improved dexterity, speed, and reliability. For users, it means a more natural and functional interaction with their advanced prosthetic devices. The system is designed for people seeking greater functionality from their artificial limbs.
Blue Arbor is developing two versions of the RESTORE platform. The external sensing unit represents the initial phase. It is currently undergoing feasibility studies. This unit allows for non-invasive testing and validation of the core technology. The long-term vision includes a fully implantable internal sensing unit. This next-generation interface will integrate seamlessly into the same RESTORE platform. It offers the promise of maximum comfort, discretion, and connectivity for users. Both versions share the goal of creating a direct, intuitive link between mind and machine.
The $10.5 million Series A funding will fuel critical development pathways. A primary objective is completing feasibility studies for the external sensing unit. These studies are essential for gathering performance data and refining the technology. The company will also pursue an FDA Investigational Device Exemption (IDE). An IDE is crucial for initiating U.S. clinical studies for the external sensing unit. These trials will validate the system's safety and effectiveness in a broader patient population. Concurrently, Blue Arbor will begin developing the fully implantable internal sensing unit. This dual-track approach ensures both immediate progress and long-term innovation.
Blue Arbor Technologies has already achieved significant milestones. The company has completed two human implantations of its technology. A successful second-in-human procedure recently occurred at the Medical University of Vienna. These initial procedures provide vital real-world data and validation. The RESTORE system has also garnered recognition from leading research institutions. It was selected for a University of Michigan clinical study. This study, backed by an NIH UG3 grant, will compare surface electrodes with implanted electrodes for prosthetic control. Such independent validation reinforces the system's scientific merit.
Regulatory bodies have also acknowledged the RESTORE system's potential. The platform received FDA Breakthrough Device Designation. This designation is reserved for technologies that offer more effective treatment or diagnosis of life-threatening or irreversibly debilitating conditions. It streamlines the regulatory review process. Furthermore, Blue Arbor has been accepted into the FDA’s Total Product Life Cycle Advisory Program Pilot. This program provides early interaction with FDA experts. Both recognitions highlight the agency’s belief in RESTORE’s transformative capacity. They signal a path toward expedited patient access.
The investment from Ottobock represents more than just capital. Ottobock is a global leader in prosthetics, neuro-orthotics, and wearable human bionics. Its involvement provides strategic partnership and deep industry expertise. Ottobock’s vast distribution network and market presence offer Blue Arbor unparalleled opportunities. This collaboration can accelerate the translation of pioneering research into scalable solutions. It positions Blue Arbor to deliver meaningful value to millions worldwide living with limb loss. The partnership creates a powerful alliance between cutting-edge innovation and established market leadership.
Blue Arbor Technologies is based in Grass Lake, Michigan. The company's mission is clear. It aims to create a direct, intuitive connection between a patient’s peripheral nervous system and a robotic prosthetic limb. This connection is the key to unlocking superior control and functionality. For individuals who have lost limbs, this technology promises a return to more natural movement. It offers increased independence and an improved quality of life. The RESTORE system represents a significant step towards fulfilling this promise.
This funding round marks a pivotal moment for Blue Arbor and the field of prosthetic control. It fuels the development of a technology poised to redefine human-machine interaction. The company is committed to closing the gap between current prosthetic technology and the needs of patients. With successful human implantations, critical FDA designations, and strong strategic backing, Blue Arbor Technologies is well-positioned. It stands ready to deliver the next generation of intuitive and precise prosthetic control systems. The future of bionic limbs looks more connected, more intuitive, and more hopeful.